All In Biotech

Drug Trial Radar · NCT06979531

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Jul 2028

Study completion Jul 2029

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
May 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).

Conditions

  • Primary Sjögren's Syndrome

Interventions

  • IMVT-1402Drug

    Administered once weekly by subcutaneous injection

  • PlaceboDrug

    Administered once weekly by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in clinESSDAI Score at Week 24 for IMVT-1402 Dose 1 compared to PlaceboTime frame: Baseline and at Week 24

Locations

96 sites in 13 countries. Site status is shown where the registry gives one.

  • Site Number - 1027

    Covina, California

  • Site Number - 1007

    El Cajon, California

  • Site Number - 1016

    Menifee, California

  • Site Number - 1029

    Thousand Oaks, California

  • Site Number - 1026

    Upland, California

  • Site Number - 1014

    Fort Collins, Colorado

  • Site Number - 1018

    Hollywood, Florida

  • Site Number - 1021

    Jupiter, Florida

  • Site Number - 1002

    Miami, Florida

  • Site Number - 1004

    Tamarac, Florida

  • Site Number - 1025

    Tampa, Florida

  • Site Number - 1012

    Chicago, Illinois

  • Site Number - 1033

    Orland Park, Illinois

  • Site Number - 1030

    Lake Charles, Louisiana

  • Site Number - 1028

    New Orleans, Louisiana

  • Site Number - 1032

    Canton, New York

  • Site Number - 1006

    Mineola, New York

  • Site Number - 1013

    Philadelphia, Pennsylvania

  • Site Number - 1015

    Jackson, Tennessee

  • Site Number - 1000

    Memphis, Tennessee

  • Site Number - 1001

    Allen, Texas

  • Site Number - 1020

    Amarillo, Texas

  • Site Number - 1022

    Arlington, Texas

  • Site Number - 1019

    Austin, Texas

  • Site Number - 1024

    Grapevine, Texas

  • Site Number - 1011

    Houston, Texas

  • Site Number - 1010

    Houston, Texas

  • Site Number - 1023

    Katy, Texas

  • Site Number - 1031

    San Antonio, Texas

  • Site Number - 5000

    Buenos Aires, Argentina

  • Site Number - 5002

    Buenos Aires, Argentina

  • Site Number - 5003

    Buenos Aires, Argentina

  • Site Number - 5001

    Buenos Aires, Argentina

  • Site number - 5006

    Buenos Aires, Argentina

  • Site number - 5005

    Azcuénaga, Buenos Aires, Argentina

  • Site Number - 5007

    Capital Federal, Buenos Aires, Argentina

  • Site Number - 5004

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Site Number - 2001

    Sherbrooke, Quebec, Canada

  • Site Number - 2000

    Trois-Rivières, Quebec, Canada

  • Site Number - 5705

    Osorno, Chile

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.